Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Common Stock Repurchased

Cash spent buying back the company's own shares.

Savara Inc.NASDAQ: SVRA

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased grows, but more slowly than its trailing trend

Q1 FY2026 common stock repurchased of $240K (cash outflow) rose 11.6% year over year, behind the +327.6% change in trailing-twelve-month common stock repurchased. Sequentially, it fell 95.0% from the prior quarter. Over 3 fiscal years it compounded at +1096.6% a year.

Context

  • Common stock repurchased grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.6% toward the trailing-twelve-month pace of +327.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$240K-95.0% QoQ
Last fiscal yearDec 2025
-$5.14M+416.6% YoY
LTMMar 2026
-$5.17M+327.6% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year+416.6%——
3-year CAGR+1096.6%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(5.14M) USD
Year-over-year change
-416.6%

Common Stock Repurchased vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 common stock repurchased of $5.17M is the smallest of the 2 companies compared; the peer median is $8.98M.
  • Its year-over-year change of +327.6% is the highest of 2, against a peer median of +296.9%.
  • Over three fiscal years its annual growth of +1096.6% compares with a peer median of -68.8%.
SVRA Competitors Peer median
Common Stock Repurchased for SVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$8.98M +296.9%-68.8%8.2%
SVRASavara Inc.LTM Mar 2026$5.17M +327.6%+1096.6%—
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $8.98M+296.9%-68.8%8.2%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Depreciation & Amortization367K167K77K130K87K
Deferred Income Tax1.7M0000
Stock-Based Compensation3.26M2.04M4.18M9.86M14.42M
Change in Working Capital(2.85M)960K4.07M1.83M5M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.76M)(319K)4.54M4.2M4.81M
Other Working Capital(1.08M)1.28M(468K)(2.37M)195K
Other Non-Cash Items449K428K(4.69M)(5.03M)(1.71M)
Operating Cash Flow(40.08M)(34.55M)(51.06M)(89.09M)(101.04M)
Capital Expenditures(57K)(9K)(296K)(25K)(22K)
Acquisitions (Net)(8.2M)056.82K00
Purchases of Investments(161.07M)(89.42M)(194.22M)(204.92M)(204.9M)
Sales of Investments91.67M142.07M137.4M165M182.2M
Other Investing Activities8.2M0(56.82K)04.28M
Investing Cash Flow(69.46M)52.65M(57.12M)(39.94M)(18.44M)
Debt Repayment088K002.37M
Common Stock Issued122.23M083.71M118.17M140.23M
Common Stock Repurchased(78K)(3K)(1.21M)(995K)(5.14M)
Dividends Paid00000
Other Financing Activities(1.35M)2K0400K0
Financing Cash Flow120.81M87K82.78M117.58M137.81M
Effect of Forex Changes(137K)(90K)(118K)(5K)(277K)
Net Change in Cash11.13M18.09M(25.52M)(11.46M)18.05M
Free Cash Flow(40.14M)(34.56M)(51.36M)(89.11M)(101.06M)

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.